Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Eisuke Murakami"'
Autor:
Masanari Kosaka, Hatsue Fujino, Masataka Tsuge, Shinsuke Uchikawa, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, C. Nelson Hayes, Shiro Oka
Publikováno v:
Livers, Vol 4, Iss 3, Pp 364-376 (2024)
The preS1 region of the large hepatitis B virus (HBV) surface protein is a crucial component in HBV infection; however, its impact on the development of hepatocellular carcinoma (HCC) remains unknown. This study investigated the relationship between
Externí odkaz:
https://doaj.org/article/281f1728ddd34a2eb174c618f49f5d04
Autor:
Yuka Matsubara, Akiyoshi Tsuboi, Issei Hirata, Akihiko Sumioka, Takeshi Takasago, Hidenori Tanaka, Ken Yamashita, Yuichi Hiyama, Hidehiko Takigawa, Eisuke Murakami, Masataka Tsuge, Yuji Urabe, Shiro Oka
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Portal hypertensive enteropathy (PHE) is a small-bowel lesion observed in patients with portal hypertension. The clinical significance of endoscopic findings in PHE remains unclear. We aimed to clarify the clinical significance an
Externí odkaz:
https://doaj.org/article/d93082ca042f48ccbfd2ae91b5963076
Autor:
Yuko Nagaoki, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Hiroshi Aikata, C. Nelson Hayes, Masataka Tsuge, Shiro Oka
Publikováno v:
Livers, Vol 4, Iss 3, Pp 352-363 (2024)
To clarify the risk factors for the aggravation of esophagogastric varices (EGVs) after hepatitis C virus (HCV) eradication with direct-acting antiviral (DAA) therapy, we enrolled 167 consecutive patients with HCV-related compensated cirrhosis who ac
Externí odkaz:
https://doaj.org/article/9561c7e746144a2781c2f6ff47ab51b5
Autor:
Kenichi Fudeyasu, Kai Ushio, Takuo Nomura, Toshihiro Kawae, Daisuke Iwaki, Yuki Nakashima, Akiko Nagao, Akira Hiramatsu, Eisuke Murakami, Shiro Oka, Yukio Mikami
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study investigated whether the progression of liver fibrosis affects the prevalence of sarcopenia and incidence of decreased gait speed in older patients with chronic liver disease (CLD). Patients with CLD aged ≥ 60 years were classif
Externí odkaz:
https://doaj.org/article/39a2470bcf31452e89431e643e16c992
Autor:
Takahiro Kinami, Shinsuke Uchikawa, Tomokazu Kawaoka, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Shiro Oka
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have be
Externí odkaz:
https://doaj.org/article/750b5eb5b5f54de5bfbf22b2506451a0
Autor:
Masami Yamauchi, Atsushi Ono, Kei Amioka, Yasutoshi Fujii, Hikaru Nakahara, Yuji Teraoka, Shinsuke Uchikawa, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, C. Nelson Hayes, Waka Ohishi, Takeshi Kishi, Mizuki Kimura, Natsumi Suzuki, Koji Arihiro, Hiroshi Aikata, Kazuaki Chayama, Shiro Oka
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Abstract Background Lenvatinib, a multiple receptor tyrosine kinase inhibitor, might exert antitumor effects via tumor immune modulation. However, changes in the tumor immune microenvironment induced by lenvatinib are poorly understood. We investigat
Externí odkaz:
https://doaj.org/article/ba99e570f9db4c279b4af8e694a6a536
Autor:
Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, C. Nelson Hayes, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new classification system for fatty liver disease. In this study, we investigated the clinical characteristics of patients with MAFLD-hepatocellular carcino
Externí odkaz:
https://doaj.org/article/571494618e314b039648ca2219373de7
Autor:
Yuki Shirane, Yasutoshi Fujii, Atsushi Ono, Hikaru Nakahara, Clair Nelson Hayes, Ryoichi Miura, Serami Murakami, Naoya Sakamoto, Shinsuke Uchikawa, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Daiki Miki, Tomokazu Kawaoka, Koji Arihiro, Masataka Tsuge, Shiro Oka
Publikováno v:
Cancers, Vol 16, Iss 7, p 1328 (2024)
The therapeutic benefits of the immunotherapeutic combination of atezolizumab and bevacizumab (Atez/Bev) in hepatocellular carcinoma (HCC) vary. Therapeutic biomarkers might help improve outcomes for HCC patients receiving Atez/Bev therapy. The role
Externí odkaz:
https://doaj.org/article/a9a570b4168048e8b5fb5cf82ce5242c
Autor:
Yuki Shirane, Eisuke Murakami, Michio Imamura, Masanari Kosaka, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Daiki Miki, Masami Yamauchi, Wataru Okamoto, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Hiroshi Aikata, Shiro Oka
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Balloon-occluded retrograde transvenous obliteration (BRTO) is a treatment option for patients with gastric varices (GVs). This study aimed to clarify the clinical significance of portal hypertension estimated by the hepatic venou
Externí odkaz:
https://doaj.org/article/5a5eb080581442ad9a005702ca2d87f1
Autor:
Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Yuji Teraoka, Hirotaka Kouno, Shintaro Takaki, Nami Mori, Keiji Tsuji, Shiro Oka
Publikováno v:
Cancers, Vol 15, Iss 22, p 5406 (2023)
A total of 137 HCC patients treated with atezolizumab plus bevacizumab from October 2020 to September 2022 were enrolled. The median overall survival (OS) and progression-free survival (PFS) from the beginning of atezolizumab plus bevacizumab were 21
Externí odkaz:
https://doaj.org/article/aeace0015ad44ea68812d0ef7a8b225f